drugset / Trial / NCT03803475

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

NCT03803475

Phase 3 Completed 485 enrolled Thomas Hope
NaSingle-groupOpen-labelDiagnostic

Summary

The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.

Timeline

Start
2018-10-11
Primary completion
2020-08-25
Completion
2020-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 3 unknown Intravenous
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 7 unknown Intravenous

Indications